SI2994533T1 - Postopki in sestave za zdravljenje raka - Google Patents

Postopki in sestave za zdravljenje raka

Info

Publication number
SI2994533T1
SI2994533T1 SI201431286T SI201431286T SI2994533T1 SI 2994533 T1 SI2994533 T1 SI 2994533T1 SI 201431286 T SI201431286 T SI 201431286T SI 201431286 T SI201431286 T SI 201431286T SI 2994533 T1 SI2994533 T1 SI 2994533T1
Authority
SI
Slovenia
Prior art keywords
cancer
compositions
treatment
methods
Prior art date
Application number
SI201431286T
Other languages
English (en)
Inventor
Laura Soucek
Marie-Eve Beaulieu
Original Assignee
Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron filed Critical Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron
Publication of SI2994533T1 publication Critical patent/SI2994533T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SI201431286T 2013-05-07 2014-05-07 Postopki in sestave za zdravljenje raka SI2994533T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20130382167 EP2801370A1 (en) 2013-05-07 2013-05-07 Methods and compositions for the treatment of cancer
PCT/EP2014/059315 WO2014180889A1 (en) 2013-05-07 2014-05-07 Methods and compositions for the treatment of cancer
EP14722204.6A EP2994533B1 (en) 2013-05-07 2014-05-07 Methods and compositions for the treatment of cancer

Publications (1)

Publication Number Publication Date
SI2994533T1 true SI2994533T1 (sl) 2019-09-30

Family

ID=48366303

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431286T SI2994533T1 (sl) 2013-05-07 2014-05-07 Postopki in sestave za zdravljenje raka

Country Status (25)

Country Link
US (2) US10370434B2 (sl)
EP (4) EP2801370A1 (sl)
JP (2) JP6722103B2 (sl)
KR (1) KR102324116B1 (sl)
CN (1) CN105378084B (sl)
AU (1) AU2014264642B2 (sl)
BR (2) BR112015028115B1 (sl)
CA (1) CA2911863A1 (sl)
CY (1) CY1121849T1 (sl)
DK (1) DK2994533T3 (sl)
EA (2) EA202090683A3 (sl)
ES (1) ES2733515T3 (sl)
HK (2) HK1219756A1 (sl)
HR (1) HRP20191330T1 (sl)
HU (1) HUE045615T2 (sl)
IL (2) IL242483B (sl)
LT (1) LT2994533T (sl)
ME (1) ME03509B (sl)
MX (1) MX370792B (sl)
PL (1) PL2994533T3 (sl)
PT (1) PT2994533T (sl)
RS (1) RS59276B1 (sl)
SG (2) SG11201509131VA (sl)
SI (1) SI2994533T1 (sl)
WO (1) WO2014180889A1 (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2801370A1 (en) 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer
US10654894B2 (en) * 2016-02-03 2020-05-19 Keenesaw State University Research And Service Foundation, Inc. Methods for delivering cargo into a cell by using signal molecules as cell penetration agents
WO2017190061A1 (en) * 2016-04-29 2017-11-02 The University Of Chicago Synthetic dna binding domain peptides and uses thereof
EP3269734A1 (en) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer
CN106591335A (zh) * 2016-11-08 2017-04-26 安徽省农业科学院水稻研究所 一种密码子植物化改造的LbCpf1基因及其应用
WO2019048679A1 (en) * 2017-09-08 2019-03-14 Idp Discovery Pharma, S.L. NEW TREATMENTS OF MULTIPLE MYELOMA
US20200354411A1 (en) * 2017-11-29 2020-11-12 Agency For Science, Technology And Research Chimeric Molecule for Targeting c-Myc in Cells
EP3773492A4 (en) * 2018-04-09 2022-01-05 Board of Regents, The University of Texas System THERAPEUTIC TARGETING OF ONCOGENS USING EXOSOMES
CN113557035A (zh) * 2019-01-12 2021-10-26 卫理公会医院 自组装肽纳米颗粒和其用途
CA3133155A1 (en) 2019-03-19 2020-09-24 Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron Combination therapy for the treatment for cancer
TWI829893B (zh) * 2019-03-19 2024-01-21 瓦爾希伯倫私人腫瘤研究基金會 診斷肺癌的方法
KR102221227B1 (ko) 2019-05-07 2021-03-03 김영화 공급자 연동과 다국어 지원 기능을 구비한 쇼핑몰 플랫폼 제공 장치 및 그 방법
EP4021934A4 (en) * 2019-08-30 2024-02-14 Univ California METHODOLOGIES FOR SCREENING FOR OVEREXPRESSION OF GENE FRAGMENTS AND RELATED USES
CN115925975A (zh) * 2022-08-03 2023-04-07 山东大学 一种靶向肿瘤干细胞的car-mφ体内外编辑制备方法以及其应用
EP4361633A1 (en) 2022-10-25 2024-05-01 Peptomyc, S.L. Method for predicting response to a cancer treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US5322801A (en) 1990-04-19 1994-06-21 The General Hospital Corporation Protein partner screening assays and uses thereof
WO1993019176A1 (en) 1992-03-23 1993-09-30 Imperial Cancer Research Technology Limited Leucine zippers
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
MX366955B (es) * 2009-09-15 2019-07-31 Bluelink Pharmaceuticals Inc Crlx101 para usarse en el tratamiento de cáncer.
DE102009052866A1 (de) * 2009-11-13 2011-05-19 Bizerba Gmbh & Co. Kg Schneidemaschine
US9155724B2 (en) 2010-02-05 2015-10-13 Whitehead Institute For Biomedical Research Combination methods for treatment of disease
NZ704191A (en) 2010-06-14 2016-05-27 Hoffmann La Roche Cell-penetrating peptides and uses therof
US9241920B2 (en) * 2011-10-27 2016-01-26 New York University Inhibition of c-Myc ubiquitination to prevent cancer initiation and progression
EP2801370A1 (en) 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
PT2994533T (pt) 2019-08-05
BR122020017819B1 (pt) 2023-11-21
US20190382468A1 (en) 2019-12-19
EA202090683A3 (ru) 2020-09-30
WO2014180889A8 (en) 2015-06-18
PL2994533T3 (pl) 2020-03-31
HK1219756A1 (zh) 2017-04-13
EA035463B1 (ru) 2020-06-19
IL273090A (en) 2020-04-30
SG11201509131VA (en) 2015-12-30
KR102324116B1 (ko) 2021-11-11
MX2015015518A (es) 2016-07-21
BR112015028115B1 (pt) 2023-11-21
EA202090683A2 (ru) 2020-06-30
JP2016520056A (ja) 2016-07-11
MX370792B (es) 2020-01-08
IL273090B (en) 2022-06-01
CN105378084B (zh) 2019-07-05
CA2911863A1 (en) 2014-11-13
IL242483B (en) 2020-03-31
EP3545966A1 (en) 2019-10-02
SG10201709101VA (en) 2017-12-28
US10370434B2 (en) 2019-08-06
LT2994533T (lt) 2019-08-12
ME03509B (me) 2020-04-20
ES2733515T3 (es) 2019-11-29
US11339205B2 (en) 2022-05-24
BR112015028115A2 (pt) 2017-10-17
DK2994533T3 (da) 2019-07-01
EP2994533B1 (en) 2019-05-01
AU2014264642A1 (en) 2015-11-19
JP6722103B2 (ja) 2020-07-15
HRP20191330T1 (hr) 2019-10-18
CN105378084A (zh) 2016-03-02
KR20160013058A (ko) 2016-02-03
US20160122415A1 (en) 2016-05-05
EP2994533A1 (en) 2016-03-16
CY1121849T1 (el) 2020-07-31
EP3338789A1 (en) 2018-06-27
HUE045615T2 (hu) 2020-01-28
EA201690159A1 (ru) 2016-05-31
EP2801370A1 (en) 2014-11-12
JP2019147792A (ja) 2019-09-05
WO2014180889A1 (en) 2014-11-13
AU2014264642B2 (en) 2020-09-17
RS59276B1 (sr) 2019-10-31
HK1251494A1 (zh) 2019-02-01
JP6790148B2 (ja) 2020-11-25

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
HK1225654A1 (zh) 用於治療老花眼的組合物及方法
IL245281A0 (en) Methods and preparations for the treatment of cancer
HK1217289A1 (zh) 使用細菌治療癌症的組合物和方法
GB201320723D0 (en) Composition and methods of treatment
IL238177A0 (en) Methods and preparations for the treatment of cancer
EP3004396A4 (en) Methods and compositions for the treatment of cancer
HK1225647A1 (zh) 用於治療癌症的組合物和方法
EP3004395A4 (en) Compositions and methods for treating cancer
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
SG10201710538XA (en) Compositions and methods for treating skin
HK1223547A1 (zh) 癌症治療方法
EP2958591A4 (en) METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF CANCER
GB201403083D0 (en) Treatment of cancer
EP2984185A4 (en) Methods and compositions for treating cancer
HK1232118A1 (zh) 癌症的治療
EP3003371A4 (en) MATERIALS AND METHODS FOR THE TREATMENT OF LIVER CANCER
IL245998A0 (en) Pharmaceutical preparations and a method for the treatment of metastatic cancer and its prevention
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
EP2971044A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
AU2014315422A1 (en) Rilyazine derivatives and compositions for the treatment of cancer
GB201322346D0 (en) Combination treatment of cancer
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
GB201308529D0 (en) Treatment of cancer